Scientific and Medical Meetings

American Epilepsy Society (AES) Annual Meeting, December 5-9, 2025

Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Regulatory Protein (TARPγ8): Impact on RNS Long Episodes and Focal Seizures

William W. Motley, MD, D.Phil; Imran H. Quraishi, MD, PhD; Neal Nolan, MD; Daniel Friedman, MD; Patrick Landazuri, MD; Vikram…

Read Now

RAP-219: A Differentiated ASM Targeting Restricted Brain Expression of γ8 Transmembrane AMPA Receptor Regulatory Protein (TARPγ8)

Stephen Greene, PharmD; Marie Cohilis, PhD; Michel Koole, PhD; Kim Serdons, PhD; Marissa Herbots, MSN; Kathleen Sierens, MD; Jan de…

Read Now

Effect of RAP-219 on Long Episodes and Clinical Seizures in Adults With Drug-Resistant Focal Seizures and an Implanted Responsive Neurostimulator (RNS) System by Baseline Disease Severity: A Post-Hoc Analysis of a Phase 2a Proof-of-Concept Study

Neal M. Nolan, MD; Daniel Friedman, MD; William W. Motley, MD; Michael Gelfand, MD, PhD; Jeff Sevigny, MD; Patrick Landazuri,…

Read Now

Effect of RAP-219 on Seizure Severity in Adults with Drug-Resistant Focal Onset Seizures and an Implanted Responsive Neurostimulator (RNS) System: Analysis of a Phase 2a Proof-of-Concept Study

Arnold R. Gammaitoni, PharmD; Jacqueline A. French, MD; Neal M. Nolan, MD; Allison Little, PharmD; Taneeta M. Ganguly, MD; Shiling…

Read Now

Safety, Tolerability, and Pharmacokinetics of RAP-219 in Healthy Volunteers

Swamy Yeleswaram, PhD; Bradley S. Galer, MD; William W. Motley, MD; Stephen Greene, PharmD

Read Now

Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219, a Negative Allosteric Modulator of the γ8 Transmembrane AMPA Receptor-Associated Regulatory Protein (TARPγ8)

William W. Motley, MD; Daniel Friedman, MD; Kathryn A. Davis, MD; Bradley S. Galer, MD; Nancy Wyant, BA; Jose A….

Read Now

Optimal Cut Point for Reduction in Long Episode Frequency to Predict Meaningful Change in Clinical Seizure Frequency

Arnold R. Gammaitoni, PharmD; Martha J. Morrell, MD; Jacqueline A. French, MD; Daniel Friedman, MD; Kathryn A. Davis, MD; Thomas…

Read Now

Evolution of RAP-219 for the Treatment of Epilepsy

Read Now

American Academy of Neurology (AAN) Annual Meeting, April 5-9, 2025

Optimal Cut Point for Reduction in Long Episode Frequency to Predict Meaningful Change in Clinical Seizure Frequency

Arnold R Gammaitoni, PharmD; Martha J. Morrell, MD; Jacqueline A French, MD; Daniel Friedman, MD; Kathryn A Davis, MD; Thomas K Tcheng, PhD; Cairn Seale, MS; Bradley S Galer, MD; William W Motley, MD

Read Now

Antiseizure Effects with Selective TARPγ8 Negative Allosteric Modulators in Preclinical Seizure Models

Jose A. Matta, PhD; Brock Shireman, PhD; Laurie Volak, PhD; Michael P. Maher, PhD; David Bredt, MD, PhD

Read Now

American Epilepsy Society (AES) Annual Meeting – December 6-10, 2024

Optimal Cut Point for Reduction in Long Episode Frequency to Predict Meaningful Change in Clinical Seizure Frequency

Arnold R Gammaitoni, PharmD; Martha J. Morrell, MD; Jacqueline A French, MD; Daniel Friedman, MD; Kathryn A Davis, MD; Thomas K Tcheng, PhD; Cairn Seale, MS; Bradley S Galer, MD; William W Motley, MD

Read Now

Safety, Tolerability, and Pharmacokinetics of RAP-219 in Healthy Volunteers

Swamy Yeleswaram, PhD; Bradley S Galer, MD; William W Motley, MD; Stephen Greene, PharmD

Read Now

Impact of Food on the PK and Tolerability of RAP-219 in Healthy Volunteers

Stephen Greene, PharmD; Swamy Yeleswaram, PhD

Read Now

Antiseizure Effects with Selective TARPγ8 Negative Allosteric Modulators in Preclinical Seizure Models

Jose A. Matta, PhD; Brock Shireman, PhD; Laurie Volak, PhD; Michael P. Maher, PhD; David Bredt, MD, PhD

Read Now

Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219, a Negative Allosteric Modulator of the γ8 Transmembrane AMPA Receptor-Associated Regulatory Protein (TARPγ8)

William W Motley, MD; Daniel Friedman, MD; Kathryn A Davis, MD; Bradley S Galer, MD; Nancy Wyant, BA; Jose A Matta, PhD; Arnold R Gammaitoni, PharmD; Dennis Dlugos, MD, MSCE; Martha Morrell, MD; Jacqueline A French, MD

Read Now

Evolution of RAP-219 for the Treatment of Epilepsy

Read Now

Epilepsy Foundation Pipeline Conference, September 25-26, 2024

RAP-219 a Novel, Potent, and Selective Negative Modulator of AMPAR/TARPγ8

Arnold Gammaitoni, Pharm.D. SVP, Medical Affairs, Rapport Therapeutics

Read Now

15th European Epilepsy Congress (EEC) 2024 – September 7-11, 2024

Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219, a Negative Allosteric Modulator of the γ8 Transmembrane AMPA Receptor Associated Protein (TARPγ8)

Jose A. Matta, PhD, Weston Davini, MS, Laurie P. Volak, PhD, Brock T. Shireman, PhD, and David Bredt, MD, PhD

Read Now

International Association for the Study of Pain (IASP) 2024 World Congress on Pain – August 5-9, 2024

RTX-1738 Exhibits Analgesic Activity Across a Broad Range of Preclinical Pain Models

Jose A. Matta, PhD, Weston Davini, MS, Laurie P. Volak, PhD, Brock T. Shireman, PhD, and David Bredt, MD, PhD

Read Now